|
The
FAP Gene Support Group
is pleased to promote the following trial
For
patients with desmoid tumors or aggressive fibromatosis -
Alliance A091105:
A
Phase III, Double Blind, Randomized, Placebo-Controlled Trial
of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis
(DT/DF).
Patient
Brochure PDF
File
Further
Information and FAQ's PDF
File
The
Alliance for Clinical Trials in Oncology (Alliance),
which is one of the five National Cancer Institute sponsored
cooperative research groups in the United States, conducting
large multicenter trials in oncology.
Relevant to sarcoma, we have recently launched trial for patients
with desmoid tumors or aggressive fibromatosis - Alliance
A091105: A Phase III, Double Blind, Randomized, Placebo-Controlled
Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis
(DT/DF).
This
pivotal trial addresses a very rare population, with less
than 1.000 cases per year, according to NCI Surveillance,
Epidemiology, and End Results (SEER) Program databases. There
are limited therapies available for desmoid tumors. More research
into the disease is needed for a possible cause and potential
treatment.
For
more information, contact the National Cancer Institute Cancer Information
Service toll-free at 1 -800-422-6237 or visit their website at www.cancer.gov.
You can also visit the Alliance website at www.AllianceforClinicalTrialsinOncology.org.
|
